Finance Monthly CFO Awards 2019 Winners Edition

www.finance-monthly.com 60 Finance Monthly CFO Awards 2019 Senior Vice President and Chief Accounting Officer of Urovant Sciences CHRISTINE G. OCAMPO ABOUT CHRISTINE G. OCAMPO Ms. Ocampo is Principal Financial and Accounting Officer of Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Joining Urovant Sciences Inc. in 2017 as Senior Vice President and Chief Accounting Officer, Ms. Ocampo has extensive experience in leading both private and public companies in accounting and finance operations, capital raising and business transactions, including over 15 years as the head of Finance for publicly traded companies in the healthcare industry. Throughout her career Ms. Ocampo has served as the finance lead in numerous business transactions including mergers, acquisitions, divestitures and licensing and has raised an excess of $825 million in capital. Her nomination for the 2019 Finance Monthly CFO Award was in recognition for her role in the initial public offering of Urovant Sciences in 2018. Prior to joining Urovant Sciences, Ms. Ocampo was the Senior Vice President and Chief Financial Officer of Otic Pharma, Ltd., until it was acquired by Novus Therapeutics (Nasdaq: NVUS), after which she served as the Chief Financial and Compliance Officer. During her tenure as CFO, Ms. Ocampo played a critical role in the 2017 acquisition of Otic Pharma by Novus and transitioned the company to a publicly traded company. Prior to joining Novus, Ms. Ocampo served in various roles at Avanir Pharmaceuticals, a publicly traded pharmaceutical company focusing on neurological disorders including Vice President of Finance, Chief Accounting Officer, Chief Compliance Officer and Secretary. During her tenure as CAO, Ms. Ocampo played a critical role in the 2015 acquisition of Avanir by Otsuka Pharmaceutical Co., Ltd. Prior to Avanir, Ms. Ocampo served as the Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer, Secretary and Vice President, Corporate Controller of Cardiogenesis Corporation (now CryoLife, Inc.), a publicly traded medical device company. Ms. Ocampo earned a B.A. in Accounting from Seattle University, a Jesuit Catholic university where she was honored to be one of the first recipients of the prestigious Sullivan Leadership Award, a four-year full tuition scholarship which recognizes academic excellence and dedication to leadership and service. Ms. Ocampo began her career in accounting as an auditor for Ernst & Young LLP and is a licensed Certified Public Accountant. FIRM PROFILE Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once- daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit www.urovant.com Finance Monthly CFO Awards 2019 USA